JP2006521286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006521286A5 JP2006521286A5 JP2005501118A JP2005501118A JP2006521286A5 JP 2006521286 A5 JP2006521286 A5 JP 2006521286A5 JP 2005501118 A JP2005501118 A JP 2005501118A JP 2005501118 A JP2005501118 A JP 2005501118A JP 2006521286 A5 JP2006521286 A5 JP 2006521286A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- fusion protein
- fragment
- cea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims 15
- 108020001507 fusion proteins Proteins 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 241001529936 Murinae Species 0.000 claims 5
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 210000001006 meconium Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 101000623904 Homo sapiens Mucin-17 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 102100023125 Mucin-17 Human genes 0.000 claims 1
- 102100034263 Mucin-2 Human genes 0.000 claims 1
- 108010008705 Mucin-2 Proteins 0.000 claims 1
- 102100022693 Mucin-4 Human genes 0.000 claims 1
- 108010008699 Mucin-4 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102000007000 Tenascin Human genes 0.000 claims 1
- 108010008125 Tenascin Proteins 0.000 claims 1
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 claims 1
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 101150061829 bre-3 gene Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical group C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- QCQYVCMYGCHVMR-AAZUGDAUSA-N n-[(2r,3r,4s,5r)-4,5,6-trihydroxy-1-oxo-3-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]acetamide Chemical compound CC(=O)N[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O QCQYVCMYGCHVMR-AAZUGDAUSA-N 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41653102P | 2002-10-08 | 2002-10-08 | |
| US60/416,531 | 2002-10-08 | ||
| PCT/US2002/032307 WO2004032962A1 (en) | 2002-10-08 | 2002-10-11 | Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents |
| USPCT/US02/32307 | 2002-10-11 | ||
| US46716103P | 2003-05-02 | 2003-05-02 | |
| US60/467,161 | 2003-05-02 | ||
| PCT/US2003/031801 WO2004032857A2 (en) | 2002-10-08 | 2003-10-08 | Antibody therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011093352A Division JP5437306B2 (ja) | 2002-10-08 | 2011-04-19 | 抗体療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006521286A JP2006521286A (ja) | 2006-09-21 |
| JP2006521286A5 true JP2006521286A5 (enExample) | 2006-11-02 |
| JP4790413B2 JP4790413B2 (ja) | 2011-10-12 |
Family
ID=34830287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501118A Expired - Fee Related JP4790413B2 (ja) | 2002-10-08 | 2003-10-08 | 抗体療法 |
| JP2011093352A Expired - Fee Related JP5437306B2 (ja) | 2002-10-08 | 2011-04-19 | 抗体療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011093352A Expired - Fee Related JP5437306B2 (ja) | 2002-10-08 | 2011-04-19 | 抗体療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US7803372B2 (enExample) |
| EP (1) | EP1572131B1 (enExample) |
| JP (2) | JP4790413B2 (enExample) |
| KR (1) | KR20050065587A (enExample) |
| CN (1) | CN101972478B (enExample) |
| AU (1) | AU2003282752A1 (enExample) |
| CA (1) | CA2501616C (enExample) |
| IL (3) | IL167901A (enExample) |
| WO (1) | WO2004032857A2 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| KR20050065587A (ko) * | 2002-10-08 | 2005-06-29 | 이뮤노메딕스, 인코오포레이티드 | 항체 치료법 |
| WO2005111208A1 (ja) * | 2004-04-27 | 2005-11-24 | Chugai Seiyaku Kabushiki Kaisha | プラズマ細胞の増殖方法 |
| EP2431050A1 (en) * | 2004-05-20 | 2012-03-21 | ZymoGenetics, L.L.C. | Methods of treating cancer using IL-21 and monoclonal antibody therapy |
| AU2006210589B2 (en) * | 2005-02-02 | 2011-12-08 | Macrogenics West, Inc. | ADAM-9 modulators |
| WO2007053189A2 (en) * | 2005-06-01 | 2007-05-10 | Northwestern University | Compositions and methods for altering immune function |
| SG10201403526YA (en) | 2005-07-25 | 2014-10-30 | Emergent Product Dev Seattle | B-cell reduction using cd37-specific and cd20-specific binding molecules |
| WO2007111714A2 (en) | 2005-11-28 | 2007-10-04 | Zymogenetics, Inc. | Il-21 antagonists |
| AU2006328882B2 (en) * | 2005-12-21 | 2011-06-16 | Amgen Research (Munich) Gmbh | Pharmaceutical antibody compositions with resistance to soluble CEA |
| AU2007257692B2 (en) | 2006-06-12 | 2013-11-14 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| CN105001332B (zh) | 2007-05-21 | 2018-12-04 | 奥尔德生物控股有限责任公司 | 针对il-6的抗体及其用途 |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| PT3281952T (pt) * | 2007-10-30 | 2020-07-23 | Philogen Spa | Um antigénio associado a artrite reumatoide |
| EP3103813A1 (en) | 2007-12-07 | 2016-12-14 | ZymoGenetics, Inc. | Anti-human il-21 monoclonal antibodies |
| WO2009088805A2 (en) | 2008-01-03 | 2009-07-16 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| ES2368700T3 (es) | 2008-04-11 | 2011-11-21 | Emergent Product Development Seattle, Llc | Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo. |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| RU2016134843A (ru) | 2009-04-30 | 2018-12-11 | Тел Хашомер Медикал Рисерч Инфрастракче Энд Сервисиз Лтд. | Антитела к ceacam1 и способы их использования |
| MY181956A (en) | 2009-07-10 | 2021-01-15 | Iii Linzy O Scott | Methods and compositions for treating thyroid-related medical conditions with reduced folates |
| CN102482701B (zh) | 2009-09-16 | 2015-05-13 | 免疫医疗公司 | I类抗-cea抗体及其使用 |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| US20120294852A1 (en) | 2009-11-24 | 2012-11-22 | Smith Jeffrey T L | Antagonists of il-6 to raise albumin and/or lower crp |
| WO2011068845A1 (en) | 2009-12-02 | 2011-06-09 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| CA2818813C (en) | 2010-11-23 | 2020-10-06 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
| CN102153655B (zh) * | 2010-12-29 | 2013-06-26 | 吉林大学 | 一种靶向抗肿瘤重组蛋白质及其制备方法 |
| ES2704038T3 (es) | 2011-05-24 | 2019-03-13 | Zyngenia Inc | Complejos multiespecíficos multivalentes y monovalentes y sus usos |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| SI2903629T1 (sl) | 2012-10-03 | 2019-09-30 | Philogen S.P.A. | Konjugat protitelesa za uporabo pri zdravljenju vnetnih črevesnih bolezni |
| AU2013328580B2 (en) | 2012-10-12 | 2016-01-21 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| BR112015013444B1 (pt) * | 2012-12-13 | 2022-11-01 | Immunomedics, Inc | Uso de um imunoconjugado |
| ES2819573T3 (es) | 2012-12-13 | 2021-04-16 | Immunomedics Inc | Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| EP2774930A1 (en) | 2013-03-07 | 2014-09-10 | Aptenia S.R.L. | Metallocene compounds and labeled molecules comprising the same for in vivo imaging. |
| MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
| CN105518018B (zh) | 2013-03-15 | 2020-04-03 | 细胞基因公司 | 修饰的t淋巴细胞 |
| US20150125386A1 (en) * | 2013-11-05 | 2015-05-07 | Immunomedics, Inc. | Humanized anti-ceacam5 antibody and uses thereof |
| KR102452349B1 (ko) | 2014-04-27 | 2022-10-11 | 페임웨이브 리미티드 | Ceacam1에 대한 인간화 항체 |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| CN106687141A (zh) | 2014-09-10 | 2017-05-17 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其缀合物 |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| KR101783907B1 (ko) | 2016-03-15 | 2017-10-10 | 다이노나(주) | ＣＤ66ｃ에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물 |
| AU2017257254B2 (en) | 2016-04-27 | 2022-02-24 | Immunomedics, Inc. | Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
| WO2018069289A1 (en) | 2016-10-11 | 2018-04-19 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| US11331380B2 (en) | 2016-10-20 | 2022-05-17 | Celgene Corporation | Cereblon-based heterodimerizable chimeric antigen receptors |
| JP2020512314A (ja) | 2017-03-27 | 2020-04-23 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | サシツズマブゴビテカンとＲＡＤ５１阻害剤を用いたＴｒｏｐ−２発現トリプルネガティブ乳癌の治療 |
| EP3606964A4 (en) | 2017-04-03 | 2020-12-09 | Immunomedics, Inc. | SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY |
| SG11202010469QA (en) | 2018-05-23 | 2020-11-27 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| EP4426727A2 (en) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| AU2023237620A1 (en) | 2022-03-23 | 2024-08-29 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
| CN115344997B (zh) * | 2022-07-11 | 2024-05-31 | 中国水利水电科学研究院 | 夏玉米植株叶片-冠层-像元尺度氮浓度协同预测方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4818709A (en) * | 1983-01-21 | 1989-04-04 | Primus Frederick J | CEA-family antigens, Anti-CEA antibodies and CEA immunoassay |
| US4970071A (en) * | 1985-01-18 | 1990-11-13 | Mcmichael John | Immunotherapeutic methods and compositions employing antigens characteristic of non human malignant neoplasms |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JPH01126558A (ja) * | 1987-07-31 | 1989-05-18 | Neorx Corp | 抗体依存性細胞性細胞毒性の測定方法 |
| US5843708A (en) * | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
| GB8800078D0 (en) | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel antibodies |
| AU625613B2 (en) | 1988-01-05 | 1992-07-16 | Novartis Ag | Novel chimeric antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5081235A (en) | 1989-07-26 | 1992-01-14 | City Of Hope | Chimeric anti-cea antibody |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US6096289A (en) | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5443953A (en) | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
| US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| US5798100A (en) | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
| IL115177A0 (en) | 1994-09-16 | 1995-12-31 | Immunomedics Inc | Phosphorus-32 labeling of antibodies for cancer therapy |
| US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US7011812B1 (en) * | 1996-05-03 | 2006-03-14 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
| JP2000510119A (ja) * | 1996-05-03 | 2000-08-08 | イムノメディクス，インコーポレイテッド | ガンに対する標的コンビネーション免疫療法 |
| CN100415772C (zh) * | 1996-10-18 | 2008-09-03 | 基因技术股份有限公司 | 抗ErbB2抗体 |
| EP1089766B1 (en) * | 1998-06-22 | 2010-03-17 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| EP1114144A1 (en) * | 1998-09-16 | 2001-07-11 | Oncopharmaceutical, Inc. | Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent |
| IL146491A0 (en) * | 1999-06-09 | 2002-07-25 | Genentech Inc | APo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM |
| MXPA01013458A (es) * | 1999-06-25 | 2002-07-30 | Genentech Inc | Anticuerpos humanizados anti-erbb2 y tratamiento con anticuerpos anti-erbb2. |
| US7906492B2 (en) * | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US20040043030A1 (en) * | 2001-07-31 | 2004-03-04 | Immunomedics, Inc. | Polymeric delivery systems |
| CA2478047C (en) * | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| PL371202A1 (en) * | 2002-04-09 | 2005-06-13 | Merck Patent Gmbh | Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine |
| WO2004032962A1 (en) * | 2002-10-08 | 2004-04-22 | Immunomedics, Inc. | Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents |
| KR20050065587A (ko) * | 2002-10-08 | 2005-06-29 | 이뮤노메딕스, 인코오포레이티드 | 항체 치료법 |
| US7727725B2 (en) * | 2006-04-27 | 2010-06-01 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
| CN102482701B (zh) * | 2009-09-16 | 2015-05-13 | 免疫医疗公司 | I类抗-cea抗体及其使用 |
-
2003
- 2003-10-08 KR KR1020057006187A patent/KR20050065587A/ko not_active Withdrawn
- 2003-10-08 CN CN2010105006839A patent/CN101972478B/zh not_active Expired - Fee Related
- 2003-10-08 WO PCT/US2003/031801 patent/WO2004032857A2/en not_active Ceased
- 2003-10-08 CA CA2501616A patent/CA2501616C/en not_active Expired - Fee Related
- 2003-10-08 US US10/680,734 patent/US7803372B2/en not_active Expired - Fee Related
- 2003-10-08 AU AU2003282752A patent/AU2003282752A1/en not_active Abandoned
- 2003-10-08 EP EP03774636.9A patent/EP1572131B1/en not_active Expired - Lifetime
- 2003-10-08 JP JP2005501118A patent/JP4790413B2/ja not_active Expired - Fee Related
-
2005
- 2005-04-07 IL IL167901A patent/IL167901A/en active IP Right Grant
-
2007
- 2007-05-01 US US11/742,725 patent/US20070202044A1/en not_active Abandoned
- 2007-10-31 US US11/932,530 patent/US7662378B2/en not_active Expired - Fee Related
-
2009
- 2009-12-16 US US12/639,298 patent/US7919090B2/en not_active Expired - Fee Related
-
2011
- 2011-02-18 US US13/030,204 patent/US8062636B2/en not_active Expired - Fee Related
- 2011-04-19 JP JP2011093352A patent/JP5437306B2/ja not_active Expired - Fee Related
- 2011-09-26 US US13/245,330 patent/US8216572B2/en not_active Expired - Fee Related
-
2012
- 2012-05-21 US US13/476,157 patent/US8535676B2/en not_active Expired - Fee Related
- 2012-08-16 IL IL221507A patent/IL221507A/en active IP Right Grant
- 2012-08-16 IL IL221508A patent/IL221508A/en active IP Right Grant
-
2013
- 2013-08-15 US US13/967,845 patent/US8778342B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006521286A5 (enExample) | ||
| CN101972478B (zh) | 抗体治疗 | |
| JP2021501162A5 (enExample) | ||
| CN100548374C (zh) | 用ⅲ类抗cea单克隆抗体和治疗剂进行联合治疗 | |
| KR20200020902A (ko) | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 | |
| CA2478047A1 (en) | Rs7 antibodies | |
| US20200079871A1 (en) | Treatment for multiple myeloma (mm) | |
| JPWO2021154761A5 (enExample) | ||
| JPWO2022076462A5 (enExample) | ||
| WO2024183643A1 (zh) | 含抗tim-3抗体的药物组合 | |
| JPWO2019228514A5 (enExample) | ||
| US20250345449A1 (en) | Anti-cd123 immunoconjugates for the treatment of blastic plasmacytoid cell neoplasm | |
| WO2024199343A1 (zh) | 抗trop2抗体联合靶向trop2的药物治疗癌症的用途 | |
| JPWO2020176748A5 (enExample) | ||
| WO2025167929A1 (zh) | 抗体药物偶联物和雄激素受体拮抗剂的联合应用 | |
| RU2025101350A (ru) | Дозирование для лечения биспецифическими антителами к fcrh5/cd3 | |
| JPWO2020245283A5 (enExample) | ||
| HK1139316B (en) | Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents | |
| HK1139316A (en) | Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents | |
| JPWO2022049526A5 (enExample) |